Radiomics signatures predicted tumor sensitivity to treatment in patients with NSCLC, offering an approach that could enhance clinical decision-making to continue systemic therapies and forecast overall survival.
No takes yet. Share an insight, caveat, or question.
Dercle et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: